In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV

Herpes simplex virus (HSV) can be genetically altered to acquire oncolytic properties so that oncolytic HSV (oHSV) preferentially replicates in and kills cancer cells, while sparing normal cells, and inducing anti-tumor immune responses. Over the last three decades, a better understanding of HSV gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahan, Nusrat, Ghouse, Shanawaz M., Martuza, Robert L., Rabkin, Samuel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473045/
https://www.ncbi.nlm.nih.gov/pubmed/34578321
http://dx.doi.org/10.3390/v13091740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473045/
https://www.ncbi.nlm.nih.gov/pubmed/34578321
http://dx.doi.org/10.3390/v13091740

Ejemplares similares